Accounting for censoring, 47.3% (95% CI, 46.6%-48.0%) of patients with type 2 diabetes and 36.3% (95% CI, 35.6%-37.0%) of patients without type 2 diabetes reinitiated a GLP-1 RA within 1 year, and 57.3% (95% CI, 56.5%-58.1%) with type 2 diabetes and 46.4% (95% CI, 45.4%-47.4%) without type 2 diabetes reinitiated a GLP-1 RA within 2 years of discontinuation (Figure 1B). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.